BackgroundIn UZ Leuven, the day clinic of Hematology experiences a yearly growth of about 5% in the number of patient contacts. Currently, standard procedures are thoroughly evaluated in order to create additional patient capacity, without losing quality of care.Aim of the studyThis study wants to compare the administration of Multigamu00ae IV 5% and 10% in hematological patients with a secondary immunodeficiency to shorten immunoglobulin infusion time without additional side effects.Study designPatients (mainly CLL and MM) already treated with Multigamu00ae 5% without side effects were selected. During Multigamu00ae 5% and Multigamu00ae 10% administration after 3-4 weeks, infusion time, time spent at the day center, IVIg-related adverse events, number of actions taken by the nursing staff and questionnaires for patient and nursing staff to assess their satisfaction with this change of infusion were evaluated.ResultsIn this second cohort of 15 patients (mainly CLL), average infusion time was reduced from 5.08 h to 2.46 h (p < 0.0001). Time spent at the day clinic was 5.92 h for 5% IVIg and 3.77 h for 10% (p < 0.0001). IVIg-related AEu2019s increased from 0 to 0.2 per patient. Nursing actions per patient decreased from 1 to 0.86. Patient and nursing satisfaction was respectively 80% and 92% in favor of Multigamu00ae 10%.ConclusionInfusion time was reduced by more than 50% using Multigamu00ae 10%, resulting in a clear preference for patients and nursing staff. 13% of patients encountered new infusion-related AEu2019s which were mild and transient. Hospitalization time was reduced by 36%. These results are similar to our first cohort (mainly MM) except for the hospitalization time which was only reduced by 8%. This can be attributed to the fact that patients in the first cohort required more concomitant treatments and staff was not yet familiarized with the new procedure. It is thus possible to reduce infusion and hospitalization time by using a 10% IVIg administration and henceforth create additional ...